The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

BACKGROUND: The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown. OBJECTIVES: To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reductions of vemurafenib and (2) simultaneous use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Knapen, Lotte M., Koornstra, Rutger H. T., Driessen, Johanna H. M., van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R., Burger, David M., de Vries, Frank, van Erp, Nielka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004282/
https://www.ncbi.nlm.nih.gov/pubmed/29644577
http://dx.doi.org/10.1007/s11523-018-0564-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004282/
https://www.ncbi.nlm.nih.gov/pubmed/29644577
http://dx.doi.org/10.1007/s11523-018-0564-3

Ejemplares similares